Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03923361

Neural and Antidepressant Effects of Propofol (Phase 2)

Status
Withdrawn
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Utah · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Not accepted

Summary

Moderate-intensity propofol treatments will be administered to participants who are non-responders at the end of Phase 1.

Conditions

Interventions

TypeNameDescription
DRUGDiprivanSimilar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.

Timeline

Start date
2019-04-16
Primary completion
2024-03-01
Completion
2024-07-01
First posted
2019-04-22
Last updated
2019-12-18

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03923361. Inclusion in this directory is not an endorsement.